tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

InhaleRx Secures Approval for Phase 1 Trial of Panic Disorder Therapy

Story Highlights
  • InhaleRx Limited is developing rapid-onset inhaled therapies for unmet medical needs.
  • The company received approval to start a Phase 1 trial for IRX-616a to treat panic disorder.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
InhaleRx Secures Approval for Phase 1 Trial of Panic Disorder Therapy

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

InhaleRx Limited ( (AU:IRX) ) just unveiled an update.

InhaleRx Limited has received approval from the Bellberry Human Research Ethics Committee to commence a Phase 1 clinical trial for its investigational therapy, IRX-616a, aimed at treating panic disorder. The trial, which will be conducted at the CMAX facility in Adelaide, will assess the safety and pharmacokinetics of a synthetic CBD aerosol delivered via inhaler to provide rapid relief for panic attacks. This development marks a significant milestone for InhaleRx as it advances its clinical program with full funding from Clendon Biotech Capital, potentially offering a new treatment option for a condition with limited current therapies.

More about InhaleRx Limited

InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid-onset inhaled therapies for unmet medical needs in pain management and mental health sectors. The company aims to secure U.S. FDA approval for its products using efficient regulatory pathways and has a funding partner providing up to $38.5 million to accelerate its development programs.

Average Trading Volume: 262,266

Technical Sentiment Signal: Hold

Current Market Cap: A$7.47M

For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1